Significantly, this biomarker is presently being integrated into clinical trials and mentioned in EAU guidelines due to promising results about its capabilities to outperform traditional serum tumor markers, such as AFP, hCGβ, and LDH, in most TGCT subtypes, with a notable exception being teratoma, in which miR-371a-3p expression is generally absent [5]. This evidence concerns the gene AFP and testicular germ cell tumor.